- Report
- January 2026
- 198 Pages
Global
From €3149EUR$3,545USD£2,743GBP
€3499EUR$3,939USD£3,048GBP
- Report
- May 2026
- 376 Pages
Global
From €5196EUR$5,850USD£4,527GBP
- Report
- January 2026
- 180 Pages
Global
From €3997EUR$4,500USD£3,482GBP
- Report
- March 2026
- 149 Pages
Global
From €3552EUR$3,999USD£3,095GBP
- Report
- December 2025
- 150 Pages
Global
From €4308EUR$4,850USD£3,753GBP
- Report
- February 2026
- 144 Pages
Global
From €3509EUR$3,950USD£3,057GBP
- Report
- August 2025
- 182 Pages
Global
From €3149EUR$3,545USD£2,743GBP
€3499EUR$3,939USD£3,048GBP
- Report
- August 2025
- 186 Pages
Global
From €3149EUR$3,545USD£2,743GBP
€3499EUR$3,939USD£3,048GBP
- Report
- January 2026
- 181 Pages
Global
From €3149EUR$3,545USD£2,743GBP
€3499EUR$3,939USD£3,048GBP
- Report
- January 2026
- 184 Pages
Global
From €3149EUR$3,545USD£2,743GBP
€3499EUR$3,939USD£3,048GBP
- Report
- February 2026
- 250 Pages
Global
From €3988EUR$4,490USD£3,475GBP
- Report
- February 2026
- 250 Pages
Global
From €3988EUR$4,490USD£3,475GBP
- Report
- February 2026
- 250 Pages
Global
From €3988EUR$4,490USD£3,475GBP
- Report
- February 2026
- 250 Pages
Global
From €3988EUR$4,490USD£3,475GBP
- Report
- February 2026
- 250 Pages
Global
From €3988EUR$4,490USD£3,475GBP
- Report
- February 2026
- 250 Pages
Global
From €3988EUR$4,490USD£3,475GBP
- Report
- February 2026
- 250 Pages
Global
From €3988EUR$4,490USD£3,475GBP
- Report
- May 2026
- 189 Pages
Global
From €5196EUR$5,850USD£4,527GBP
- Report
- January 2026
- 281 Pages
Global
From €2221EUR$2,500USD£1,935GBP
- Report
- October 2025
- 160 Pages
Global
From €2982EUR$3,358USD£2,598GBP
€3509EUR$3,950USD£3,057GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more